Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MannKind’s Future Uncertain After Sanofi Terminates Afrezza Deal

This article was originally published in The Pink Sheet Daily

Executive Summary

During a very brief investor call, MannKind says it is planning to change its pricing and contracting tactics, after being left in the lurch as Sanofi terminates its development and commercialization deal on the inhaled insulin Afrezza.

You may also be interested in...



Afrezza Approval Comes With Post-Marketing Trial On Lung Cancer, CV Risk

FDA’s unusually specific request suggests continued worries about safety of MannKind’s inhalable insulin; large trial (8,000-10,000 type 2 diabetics) has a variety of goals.

Pfizer's COVID-19 Vaccine Commercialization Plan Includes DTC Campaign

The company is planning a direct-to-consumer education campaign to inform the public about the importance of vaccination.

A Slimmed-Down Pfizer Sets A New R&D Goal: 25 Launches By 2025

The company showcased its pipeline in a two-day virtual meeting, trying to convince investors the long-term potential is undervalued.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

MT125529

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel